대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	Chronic kidney disease(CKD) patients are exposed to more proton pump inhibitor(PPI)s compared to non-CKD patients; in a single center out-patient clinic
저자	Lee HEE JEONG, Haekyung LEE, Song hee OH, Joonbyung PARK, Jin seok JEON, Hyunjin NOH, Dong cheol HAN, *Soon hyo KWON
출판정보	2017; 2017(1):
키워드	Proton-pump inhibitors, Chronic kidney disease, Prescription
초록	Objectives : Proton pump inhibitor (PPI) is associated with incident chronic kidney disease (CKD), CKD progression and end-stage renal disease (ESRD). However, the extent of PPI prescription in CKD patients is still unclear. Methods : We conducted a retrospective single center study on patients (>18 years old) who received PPI in the out-patient from 2014 through 2015. The PPI prescription patterns and their characteristics were analyzed according to individual kidney function of the patients. Results : Our sample consisted of 9,067 patients. 50.3% were females. CKD (eGFR<60mL/min) patients were 9.8%. Among them, 720 (7.9%) were categorized as stage 3 or 4, 174 (1.9%) were stage 5 or ESRD. Total 7 different kinds of PPIs were prescribed. During the study period, median duration of PPI usage was 120 days[interquartile range, 63-273] in CKD 3-4 group, 105 days[56-271] in CKD 5-ESRD group and 90 days[56-175] in non-CKD group. CKD stage 3 or 4 group took longer duration of PPI than non-CKD group (p<0.0001). Main departments of medicine which prescribed PPIs in CKD group were gastroenterology (39.4%), cardiology (28.2%), nephrology (15.1%) and neurology (4.3%). Compared to the non-CKD group, the CKD stage 3-4 and CKD stage 5-ESRD group was taking more drugs simultaneously (6.9 ± 4.2 vs 4.5 ± 2.4; p<0.001 , 5.6 ± 2.8 vs 4.5 ± 2.4 ; p<0.001, respectively). Conclusions : CKD patients are exposed to more PPIs compared to non-CKD patients. Physicians should pay careful attention when prescribing PPIs in patients with CKD.
원문(PDF)	PDF 원문보기

목록

위로가기